# EDGAR Filing Document

**Accession Number:** 0001497130
**File Stem:** 0001903596-23-000211
**Filing Date:** 2023-3
**Character Count:** 21227
**Document Hash:** 633c1e246ced133cc6aef1b389bef74a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001903596-23-000211.hdr.sgml**: 20230322

**ACCESSION NUMBER**: 0001903596-23-000211

**CONFORMED SUBMISSION TYPE**: C-AR

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230322

**DATE AS OF CHANGE**: 20230322

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nano Mobile Healthcare, Inc.
- **CENTRAL INDEX KEY:** 0001497130
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEASURING & CONTROLLING DEVICES, NEC [3829]
- **IRS NUMBER:** 980659770
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** C-AR
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 020-28829
- **FILM NUMBER:** 23752731

**BUSINESS ADDRESS:**
- **STREET 1:** ONE BOSTON PLACE,
- **STREET 2:** SUITE 2600
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 62108
- **BUSINESS PHONE:** 617-336-7100

**MAIL ADDRESS:**
- **STREET 1:** ONE BOSTON PLACE,
- **STREET 2:** SUITE 2600
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 62108

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Vantage mHealthcare, Inc.
- **DATE OF NAME CHANGE:** 20150108

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Vantage Health
- **DATE OF NAME CHANGE:** 20100721

### Attached PDF Documents

**Attachment 1:** `vnth_car.pdf`

# **UNITED STATES**

# **SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

# **FORM C-AR**

# **UNDER THE SECURITIES ACT OF 1933**

For the fiscal year ended: December 31, 2022

(Mark one.)

Form C: Offering Statement

Form C-U: Progress Update

Form C/A: Amendment to Offering Statement

☐ Check box if Amendment is material and investors must reconfirm within five business days.

Form C-AR: Annual Report

Form C-AR/A: Amendment to Annual Report

Form C-TR: Termination of Reporting

*Name of issuer*

Nano Mobile Healthcare, Inc.

*Legal status of issuer*

Corporation

*Jurisdiction of Incorporation/Organization*

Delaware

*Date of organization*

April 21, 2010

# *Physical address of issuer*

ONE BOSTON PLACE, SUITE 2600, BOSTON, MASSACHUSETTS, 62108

# *Website of issuer*

www.vnthotc.com

# *Current number of employees*

3

|  | Most recent fiscal year-end December 31, 2022 | Prior fiscal year-end December 31, 2021 |
| --- | --- | --- |
| Total Assets | $2,250 | $0 |
| Cash & Cash Equivalents | $0 | $0 |
| Accounts Receivable | $0 | $0 |
| Short-term Debt | $5,670 | $0 |
| Long-term Debt | $510,000 | $0 |
| Revenues/Sales | $0 | $0 |
| Cost of Goods Sold | $0 | $0 |
| Taxes Paid | $0 | $0 |
| Net Income | $0 | $0 |

December 31, 2022

Form C-AR

# Nano Mobile Healthcare, Inc.

This Form C-AR (including the cover page and all exhibits attached hereto, the 'Form C- AR) is being furnished by Nano Mobile Healthcare, Inc., a Delaware corporation (the 'Company,' as well as references to 'we,' 'us,' or 'our') for the sole purpose of providing certain information about the Company as required by the Securities and Exchange Commission ('SEC').

No federal or state securities commission or regulatory authority has passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the accuracy or completeness of any disclosure document or literature. The Company is filing this Form C-AR pursuant to Regulation CF (§ 227.100 et seq.) which requires that it must file a report with the Commission annually and post the report on its website at no later than 120 days after the end of each fiscal year covered by the report. The Company may terminate its reporting obligations in the future in accordance with Rule 202(b) of Regulation CF (§ 227.202(b)) by 1) being required to file reports under Section 13(a) or Section 15(d) of the Exchange Act of 1934, as amended, 2) filing at least one annual report pursuant to Regulation CF and having fewer than 300 holders of record, 3) filing annual reports for three years pursuant to Regulation CF and having assets equal to or less than $10,000,000, 4) the repurchase of all the Securities sold pursuant to Regulation CF by the Company or another party, or 5) the liquidation or dissolution of the Company.

The date of this Form C-AR is 3/22/2023.

THIS FORM C-AR DOES NOT CONSTITUTE AN OFFER TO PURCHASE OR SELL SECURITIES.

---

2

# Forward Looking Statement Disclosure

*This Form C-AR and any documents incorporated by reference herein or therein contain forward-looking statements and are subject to risks and uncertainties. All statements other than statements of historical fact or relating to present facts or current conditions included in this Form C-AR are forward-looking statements. Forward-looking statements give the Company's current reasonable expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as 'anticipate,' 'estimate,' 'expect,' 'project,' 'plan,' 'intend,' 'believe,' 'may,' 'should,' 'can have,' 'likely' and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events.*

*The forward-looking statements contained in this Form C-AR and any documents incorporated by reference herein or therein are based on reasonable assumptions the Company has made in light of its industry experience, perceptions of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. As you read and consider this Form C-AR, you should understand that these statements are not guarantees of performance or results. They involve risks, uncertainties (many of which are beyond the Company's control) and assumptions. Although the Company believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect its actual operating and financial performance and cause its performance to differ materially from the performance anticipated in the forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of these assumptions prove incorrect or change, the Company's actual operating and financial performance may vary in material respects from the performance projected in these forward-looking statements.*

*Any forward-looking statement made by the Company in this Form C-AR or any documents incorporated by reference herein or therein speaks only as of the date of this Form C- AR. Factors or events that could cause our actual operating and financial performance to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.*

---

3

# Table of Contents

| SUMMARY | 6 |
| --- | --- |
| The Business | 6 |
| RISK FACTORS | 7 |
| Risks Relating to the Company's Business and Industry | 7 |
| Risks Relating to Our Industry | 9 |
| BUSINESS | 10 |
| History | 10 |
| Business Outlook | 10 |
| Customer Base | 10 |
| Competition | 11 |
| Intellectual Property | 11 |
| Governmental/Regulatory Approval and Compliance | 11 |
| Litigation | 11 |
| DIRECTORS, OFFICERS, AND EMPLOYEES | 12 |
| Indemnification | 12 |
| Employees | 13 |
| CAPITALIZATION AND OWNERSHIP | 13 |
| Capitalization | 13 |
| Ownership | 17 |
| FINANCIAL INFORMATION | 17 |

4

Recent Tax Return Information 18
**OPERATIONS** **18**
Cash and Cash Equivalents 18
Liquidity and Capital Resources 18
Capital Expenditures and Other Obligations 18
**MATERIAL CHANGES AND OTHER INFORMATION** **18**
Trends and Uncertainties 18
Restrictions on Transfer 18
**TRANSACTIONS WITH RELATED PERSONS AND CONFLICTS OF INTEREST** **19**
Related Person Transactions 19
Conflicts of Interest 19
**OTHER INFORMATION** **19**
Compliance with Ongoing Reporting Requirements 19
Bad Actor Disclosure 19

5

# About this Form C-AR

You should rely only on the information contained in this Form C-AR. We have not authorized anyone to provide you with information different from that contained in this Form C-AR. You should assume that the information contained in this Form C-AR is accurate only as of the date of this Form C-AR, regardless of the time of delivery of this Form C-AR. Our business, financial condition, results of operations, and prospects may have changed since that date.

Statements contained herein as to the content of any agreements or other documents are summaries and, therefore, are necessarily selective and incomplete and are qualified in their entirety by the actual agreements or other documents.

# SUMMARY

The following summary is qualified in its entirety by more detailed information that may appear elsewhere in this Form C-AR and the Exhibits hereto.

Nano Mobile Healthcare, Inc. (the 'Company' or 'VNTH') is a Delaware corporation, incorporated/formed on January 9, 2015.

The Company's headquarters is located at ONE BOSTON PLACE, SUITE 2600, BOSTON, MASSACHUSETTS, 02108

The Company's website is www.vnthotc.com The information available on or through our website is not a part of this Form C-AR.

# The Business

Nano Mobile Healthcare, Inc, formally Vantage Healthcare, Inc (the 'Company') was incorporated in Nevada on April 21, 2010. On September 15, 2022, Mr. Adam Matruski purchased the control block of share in the Company and became the sole Officer and Director of the company. Mr. Frank I Igwealor, who sold the control block to Mr. Matruski, had previously purchased the control block of shares in the company on August 2, 2021. We believe that there are assets that past management along with predatory lenders have mis-managed and we intend to vigorously enforce the rights of the company. We intend to use part of the fund from this offering to do a forensic audit to identify assets that belong to the company. Management intends

6

to develop and deploy a personalized point of care screening using Nano molecular technology found in the human breath. Building on the established success of existing breathalyzer framework, Nano Mobile Healthcare is focused on identifying and creating other avenues for non-invasive solutions in healthcare. The solution is expected to improve people’s lives and provide healthcare providers with optional real-time monitoring of patients away from the office. The targeted markets include the USA, Canada, Europe, South Africa and the Asia-Pacific region.

---

7

# RISK FACTORS

In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document.

The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature.

These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.

*Readers and prospective investors in our common stock should carefully consider the following risk factors as well as the other information contained or incorporated by reference in our prospectus.*

*If any of the following risks actually occurs, our financial condition, results of operations and liquidity could be materially adversely affected. If this were to happen, the value of our common stock could decline, and if you invest in our common stock, you could lose all or part of your investment.*

*The discussion below highlights some important risks we have identified related to our business and operations and an investment in shares of our common stock, but these should not be assumed to be the only factors that could affect our future performance and condition, financial and otherwise. We do not have a policy of updating or revising forward-looking statements except as otherwise required by law, and silence by management over time should not be construed to mean that actual events are occurring as estimated in such forward-looking statements.*

*The SEC requires the company to identify risks that are specific to its business and its financial condition.*

## Risks Relating to Investing in a Start-up Company

Investing in early-stage companies is very risky, highly speculative, and should not be made by anyone who cannot afford to lose their entire investment. Unlike an investment in a mature business where there is a track record of revenue and income, the success of a startup or early-stage venture often relies on the development of a new product or service that may or may not find a market. Before investing, you should carefully consider the specific risks and disclosures related to both this offering type and the company.

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your investment

## Risks Relating to the Company's Business and Industry

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment.

8

# **NANO MOBILE HEALTHCARE, INC.**  
**Notes to Financial Statements**  
**For the Twelve Months Ended Dec. 31, 2022 and Dec. 31, 2021**---

# **NOTE 5. LITIGATION, COMMITMENTS AND CONTINGENCIES**

# Risks and Uncertainties

The Company's operations are subject to significant risks and uncertainties including financial, operational and regulatory risks, including the potential risk of business failure.

The Company has entered into no contracts during the year as follows:

# Legal and other matters

In the normal course of business, the Company may become a party to litigation matters involving claims against the Company. The Company's management is aware of a garnishment order that was previously served to the Company's Stock Transfer Agents. The Company's attorneys are reviewing the garnishment order to ascertain its implication to the company's financial statements. Aside from the court order discussed above, The Company's management is unaware of any pending or threatened assertions and there are no current matters that would have a material effect on the Company's financial position or results of operations.

# **Note 6. SICK LEAVE, VACATION AND OTHER COMPENSATED ABSENCES**

Nano Mobile Healthcare, Inc. is in conformity with the state Labor Laws and Regulations, Family Care and Medical Leave, and Prohibits Workplace Discrimination.

# **NOTE 7. CONCENTRATIONS OF CREDIT AND MARKET RISK**

The Nano Mobile Healthcare, Inc. maintains substantially all of their cash balances in deposit accounts that at times may exceed Federally insured limits. The Nano Mobile Healthcare, Inc. has not experienced any losses in such accounts. The Nano Mobile Healthcare, Inc. believes they are not exposed to any significant credit risk related to these deposit accounts.

Financial instruments that potentially expose the Company to concentrations of credit and market risk consist primarily of cash and cash equivalents. Cash and cash equivalents are maintained at financial institutions and accounts at each institution are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. At December 31, 2022 and 2021, the Nano Mobile Healthcare, Inc. had $0, of uninsured balances at these institutions.

# **NOTE 8. RELATED PARTY TRANSACTIONS**

The Company is authorized to issue 100,000,000,000 shares of common stock, $0.001 par value and 50,000,000 preferred stocks, $0.001 par value. Voting rights are not cumulative and,

---

Page 12

# **NANO MOBILE HEALTHCARE, INC.**  
**Notes to Financial Statements**  
**For the Twelve Months Ended Dec. 31, 2022 and Dec. 31, 2021**---

# **NOTE 8. RELATED PARTY TRANSACTIONS (Continued)**

therefore, the holders of more than 50% of the common stock could, if they chose to do so, elect all of the directors of the Company.

As of December 31, 2021, there were 3,273,765,298 shares of common stock issued and outstanding. The company issued 335,000,000 shares of common stock during twelve months ended December 31, 2022. So, there were 3,273,765,298 shares of common stock issued and outstanding as of December 31, 2021. As of December 31, 2022 and 2021, there were 50,000,000 share of preferred stock issued and outstanding held by 1 stockholder of record.

# **NOTE 9. COVID 19**

The outbreak of Novel Coronavirus (COVID 19) continues to progress and evolve. Therefore, it is challenging now, to predict the full extent and duration of its business and economic impact. The extent and duration of such impacts remain uncertain and dependent on future developments that cannot be accurately predicted at this time, such as the transmission rate of the coronavirus and the extent and effectiveness of containment actions taken. Given the ongoing economic uncertainty, a reliable estimate of the impact cannot be made at the date of authorization of these financial statements. These developments could impact our future financial results, cash flows and financial condition however the management of the Company was hopeful that it will not significantly impact the business of the Company.

# **NOTE 10. GOING CONCERN**

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. The Company currently has no operations with $12,066,296 accumulated loss as of December 31, 2021. The Company intends to commence operations as set out below and raise the necessary funds to carry out the aforementioned strategies. The Company cannot be certain that it will be successful in these strategies even with the required funding.

These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

---

Page 13

## **SUPPLEMENTAL INFORMATION**

Page 14

# **NANO MOBILE HEALTHCARE, INC.**  
 **SUPPLEMENTARY SCHEDULE**  
 **GENERAL AND ADMINISTRATION EXPENSES**  
 **For the Twelve Months Ended Dec. 31, 2022 and Dec. 31, 2021**

|  | Twelve Months Ended 2022 | Twelve Months Ended 2021 |
| --- | --- | --- |
| General and administrative expenses |  |  |
| Payroll Expenses | $ - | $ - |
| Professional & contracted Services | (700) | (1,950) |
| Advertising | (399) | - |
| Sec filing | (238) | - |
| Legal Fee | - | - |
| Insurance | - | - |
| Computer & related expenses | - | - |
| Repairs and maintenance | (133) | - |
| Telephone | - | - |
| Postage | - | - |
| Office Supplies | - | - |
| Rent | - | - |
| Depreciation | - | - |
| Bank Charges | - | - |
| Other Business Expenses | - | - |
| Total General and Administrative expenses | $(1,470) | $(1,950) |

---

Page 15

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM C

### UNDER THE SECURITIES ACT OF 1933

### Issuer Information

**Name of Issuer:** Nano Mobile Healthcare, Inc.

**Legal Status:** Corporation

**Jurisdiction of Incorporation/Organization:** DE

**Date of Organization:** 04-21-2010

**Physical Address:** ONE BOSTON PLACE,, BOSTON, MA, 62108

**Issuer Website:** www.vnthotc.com

**Is there a Co-Issuer?:** No

### Offering Information

**Oversubscription Accepted:** No

### Annual Report Disclosure Requirements

**Current Number of Employees:** 3.00

**Total Assets (Most Recent Fiscal Year):** $2,250.00

**Total Assets (Prior Fiscal Year):** $0.00

**Cash & Cash Equivalents (Most Recent Fiscal Year):** $0.00

**Cash & Cash Equivalents (Prior Fiscal Year):** $0.00

**Accounts Receivable (Most Recent Fiscal Year):** $0.00

**Accounts Receivable (Prior Fiscal Year):** $0.00

**Short-Term Debt (Most Recent Fiscal Year):** $5,670.00

**Short-Term Debt (Prior Fiscal Year):** $0.00

**Long-Term Debt (Most Recent Fiscal Year):** $510,000.00

**Long-Term Debt (Prior Fiscal Year):** $0.00

**Revenues/Sales (Most Recent Fiscal Year):** $0.00

**Revenues/Sales (Prior Fiscal Year):** $0.00

**Cost of Goods Sold (Most Recent Fiscal Year):** $0.00

**Cost of Goods Sold (Prior Fiscal Year):** $0.00

**Taxes Paid (Most Recent Fiscal Year):** $0.00

**Taxes Paid (Prior Fiscal Year):** $0.00

**Net Income (Most Recent Fiscal Year):** $0.00

**Net Income (Prior Fiscal Year):** $0.00

### Signatures

**Issuer:** Nano Mobile Healthcare, Inc.

**Signature:** /s/ Adam Matruski

**Title:** President and Chief Executive Officer

---

**Signature:** /s/ Adam Matruski

**Title:** President and Chief Executive Officer

**Date:** 03-22-2023